Welcome to GBMtrial.com

This website has been designed to provide information about the Phase III clinical trial of Transferrin-CRM107 (Tf-CRM107, proposed trade name TransMIDTM), for the potential treatment of non-operable, progressive and/or recurrent glioblastoma multiforme, a type of brain cancer commonly referred to as GBM. This clinical trial is a research study designed to compare this investigational drug, Tf-CRM107, with the best standard of care treatment currently available.

The content of this site is for informational purposes only. Please consult your doctor to determine if you are an appropriate candidate for this trial.